Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Open access

Abstract

In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I–III (body mass index (BMI) 30.0–34.9 kg m − 2 , 35.0–39.9 kg m − 2 and ≥40 kg m − 2 ) and according to body weight reduction with semaglutide after 52 weeks. Semaglutide consistently improved all outcomes across obesity categories ( P value for treatment effects × BMI interactions = not significant for all). In semaglutide-treated patients, improvements in KCCQ-CSS, 6MWD and CRP were greater with larger body weight reduction (for example, 6.4-point (95% confidence interval (CI): 4.1, 8.8) and 14.4-m (95% CI: 5.5, 23.3) improvements in KCCQ-CSS and 6MWD for each 10% body weight reduction). In participants with obesity phenotype of HFpEF, semaglutide improved symptoms, physical limitations and exercise function and reduced inflammation and body weight across obesity categories. In semaglutide-treated patients, the magnitude of benefit was directly related to the extent of weight loss. Collectively, these data support semaglutide-mediated weight loss as a key treatment strategy in patients with obesity phenotype of HFpEF. ClinicalTrials.gov identifier: NCT04788511 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02526-x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Effects of semaglutide compared to placebo across different obesity classes on HF symptoms, physical limitations and body weight. a,b, There was no evidence of heterogeneity in the effects of semaglutide compared to placebo on the dual primary endpoints of KCCQ-CSS (a) or body weight (b). Data are point estimates and 95% CIs. Analyses using the intention-to-treat principle employ an F-test for interaction and a Wald test for treatment effect within BMI subgroups, with 1,000 imputations using Rubin’s rule. Analyses using on-treatment data employ an F-test for interaction and a t-test for treatment effect within BMI subgroups. P values are two-sided. ETD, estimated treatment difference.
Fig. 1 Effects of semaglutide compared to placebo across different obesity classes on HF symptoms, physical limitations and body weight. a,b, There was no evidence of heterogeneity in the effects of semaglutide compared to placebo on the dual primary endpoints of KCCQ-CSS (a) or body weight (b). Data are point estimates and 95% CIs. Analyses using the intention-to-treat principle employ an F-test for interaction and a Wald test for treatment effect within BMI subgroups, with 1,000 imputations using Rubin’s rule. Analyses using on-treatment data employ an F-test for interaction and a t-test for treatment effect within BMI subgroups. P values are two-sided. ETD, estimated treatment difference.CC BY · PubMed Central
Fig. 2 Effects of semaglutide compared to placebo across different obesity classes on exercise function, hierarchical composite endpoint and systemic inflammation. a,b, There was no evidence of heterogeneity in the effects of semaglutide compared to placebo on the confirmatory secondary endpoints of exercise function assessed by 6MWD (a), the hierarchical composite endpoint (b) or systemic inflammation assessed by CRP levels. Data are point estimates and 95% CIs. Analyses using the intention-to-treat principle employ an F-test (a,c) or Cohran’s Q-test (b) for interaction and a Wald test for treatment effect within BMI subgroups, with 1,000 imputations using Rubin’s rule. Analyses using on-treatment data employ an F-test for interaction and a t-test for treatment effect within BMI subgroups (a,c) or Cohran’s Q-test (b) for interaction and a Wald test for treatment effect within BMI subgroups. P values are two-sided. Other abbreviations as in Fig. 1.
Fig. 2 Effects of semaglutide compared to placebo across different obesity classes on exercise function, hierarchical composite endpoint and systemic inflammation. a,b, There was no evidence of heterogeneity in the effects of semaglutide compared to placebo on the confirmatory secondary endpoints of exercise function assessed by 6MWD (a), the hierarchical composite endpoint (b) or systemic inflammation assessed by CRP levels. Data are point estimates and 95% CIs. Analyses using the intention-to-treat principle employ an F-test (a,c) or Cohran’s Q-test (b) for interaction and a Wald test for treatment effect within BMI subgroups, with 1,000 imputations using Rubin’s rule. Analyses using on-treatment data employ an F-test for interaction and a t-test for treatment effect within BMI subgroups (a,c) or Cohran’s Q-test (b) for interaction and a Wald test for treatment effect within BMI subgroups. P values are two-sided. Other abbreviations as in Fig. 1.CC BY · PubMed Central
Fig. 3 Relationship between the magnitude of body weight reduction on semaglutide and primary and confirmatory secondary endpoints. a–c, Greater body weight reduction with semaglutide was associated with greater improvements in HF symptoms and physical limitations assessed by the KCCQ-CSS (a), exercise function assessed by the 6MWD (b) and greater reduction in systemic inflammation assessed by CRP levels (c). Data are point estimates and 95% CIs. Analyses use the intention-to-treat principle; tests for trend are based on an F-test. P values are two-sided. Abbreviations as in Figs. 1 and 2.
Fig. 3 Relationship between the magnitude of body weight reduction on semaglutide and primary and confirmatory secondary endpoints. a–c, Greater body weight reduction with semaglutide was associated with greater improvements in HF symptoms and physical limitations assessed by the KCCQ-CSS (a), exercise function assessed by the 6MWD (b) and greater reduction in systemic inflammation assessed by CRP levels (c). Data are point estimates and 95% CIs. Analyses use the intention-to-treat principle; tests for trend are based on an F-test. P values are two-sided. Abbreviations as in Figs. 1 and 2.CC BY · PubMed Central
Extended Data Fig. 1 Participant flow diagram.
Extended Data Fig. 1 Participant flow diagram.CC BY · PubMed Central
Extended Data Fig. 2 Relationship between the magnitude of body weight reduction on semaglutide with change in KCCQ-CSS (a); 6MWD (b); and ratio of CRP to baseline (c) in the on-treatment (per protocol) analysis. Data are point estimates and 95% CIs. Tests for trend are based on an F-test; P values are two-sided.
Extended Data Fig. 2 Relationship between the magnitude of body weight reduction on semaglutide with change in KCCQ-CSS (a); 6MWD (b); and ratio of CRP to baseline (c) in the on-treatment (per protocol) analysis. Data are point estimates and 95% CIs. Tests for trend are based on an F-test; P values are two-sided.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 1

  1. Kosiborod, M. N. et al. Once weekly semaglutide in heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. (in the press).

Cited by

See all 227

Metadata

Authors
Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., Shah, S. J., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Núñez, J., Perna, E., Schou, M., Senni, M., van der Meer, P., Von Lewinski, D., Wolf, D., & Kosiborod, M. N.
Affiliations
  • Mayo Clinic (US)
  • Wake Forest University Health Sciences (US)
  • University of Leicester (GB)
  • Novo Nordisk (Denmark) (DK)
  • University of Mississippi (US)
  • University of Glasgow (GB)
  • Northwestern University (US)
  • St. Michael's Hospital (CA)
  • Australian National University (AU)
  • University of Manchester (GB)
  • Max Super Speciality Hospital (IN)
  • University of Alberta (CA)
  • Sahlgrenska University Hospital (SE)
  • Kawasaki Medical School (JP)
  • Medical University of Lodz (PL)
  • Universitat de València (ES)
  • University of Copenhagen (DK)
  • Ospedale Papa Giovanni XXIII (IT)
  • University Medical Center Groningen (NL)
  • Medical University of Graz (AT)
  • University of Freiburg (DE)
  • Saint Luke's Hospital (US)
Corresponding author
Kosiborod, Mikhail N.
Venue
Nature Medicine
Published
2023-08-27
Volume
29
Issue
9
Pages
2358-2365
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4386203424
Cited by
215
References
16
Citations by year
2026: 44 · 2025: 72 · 2024: 89 · 2023: 10
FWCI
42.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by)
  • BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
  • Greater South Information System
Funders
  • U.S. Department of Defense (W81XWH2210245)
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company (R01 HL128526, R01 HL162828, U01 HL160226)
  • Pfizer
  • AstraZeneca (RE/18/6/34217)
  • GlaxoSmithKline
  • Sanofi
  • Heart and Stroke Foundation of Canada
  • Gilead Sciences
  • Alnylam Pharmaceuticals
  • Edwards Lifesciences
  • Northwestern University
  • United Therapeutics Corporation (R01 HL127028, R01 HL140731, R01 HL107577)
  • University of Missouri
  • Boston Scientific Corporation
  • University of Missouri-Kansas City
  • Regeneron Pharmaceuticals
  • LivaNova
  • Amarin Corporation
  • Cytokinetics
  • Prothena
  • MyoKardia
  • Saint Luke's Health System
  • NGM Biopharmaceuticals
  • Impulse Dynamics
  • University of Alberta
  • National Institute for Health and Care Research
  • British Heart Foundation (18/6/34217, RE/18/6/34217, RE/13/5/30177)
  • University of Glasgow
  • Australian National University
  • Deutsche Forschungsgemeinschaft (SFB 1425)
  • Rijksuniversiteit Groningen
  • Albert-Ludwigs-Universität Freiburg
  • Gentofte Hospital
  • Daiichi-Sankyo
  • Gedeon Richter
  • University of Toronto
  • Novo Nordisk (NCT04788511)
  • Universitair Medisch Centrum Groningen
  • Uniwersytet Łódzki
  • Sahlgrenska Universitetssjukhuset
  • Karl-Franzens-Universität Graz
  • Kawasaki Medical School
  • Medizinische Universität Graz
  • Servier
  • Sun Pharma
  • INCLIVA Instituto de Investigación Sanitaria
  • HLS Therapeutics
  • National Institutes of Health (W81XWH2210245, SFB1425, UL1TR001873, UL1TR002384)
  • Feinberg School of Medicine
  • American Regent
  • Canadian Institutes of Health Research
  • Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg
  • National Institute on Aging (U01AG076928, R01AG018915, R01AG045551, P30AG021332, U24AG059624, R01AG078153)
  • National Heart, Lung, and Blood Institute (R01HL128526, R01HL127028, R01HL149423, R01HL140731, R01HL107577, U01HL160226, U54HL160273, R01HL162828, U01HL160272)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
semaglutide, heart failure with preserved ejection fraction, obesity phenotypes, weight loss, obesity class, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, inflammation, GLP-1 receptor agonists
MeSH terms
Semaglutide, Body Weight, C-Reactive Protein, Heart Failure, Humans, Obesity, Stroke Volume, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. https://app.cochat.ai/papers/10.1038/s41591-023-02526-x
The paper
Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., Shah, S. J., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., . . . Kosiborod, M. N. (2023). Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02526-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.